Celldex Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing antibody-based therapeutics in immunology and mast cell-mediated disease. Its 8-K reports furnish financial results and corporate updates, including clinical and regulatory disclosures for barzolvolimab programs and other pipeline candidates, as well as material-event and capital-structure disclosures related to common stock financing.
Proxy materials describe annual stockholder voting matters, director elections, auditor ratification, executive compensation and equity incentive plan proposals. The filing record also identifies Celldex common stock, par value $.001, trading under CLDX on the Nasdaq Capital Market.
Celldex Therapeutics reported a larger net loss for the first quarter of 2026 as it accelerated investment in its late-stage pipeline and strengthened its balance sheet. Net loss was $78.7 million, or ($1.18) per share, compared to $53.8 million, or ($0.81), a year earlier, driven mainly by higher barzolvolimab clinical and manufacturing costs.
Cash, cash equivalents and marketable securities were $451.5 million as of March 31, 2026. In April, Celldex closed a follow-on underwritten public offering of 11,896,750 shares, generating $345.0 million in gross proceeds and approximately $323.9 million in net proceeds, which management believes will fund operations through 2028.
Operationally, enrollment in the Phase 3 chronic spontaneous urticaria barzolvolimab program (EMBARQ-CSU1 and CSU2) was completed six months ahead of guidance, with 1,939 patients enrolled across 43 countries. Multiple additional barzolvolimab Phase 2 and 3 studies, and the CDX-622 bispecific program, are progressing with several data readouts expected in 2026 and a planned BLA filing for barzolvolimab in 2027.
FMR LLC amended its Schedule 13G/A to report beneficial ownership of 3,749,048.03 shares of CellDex Therapeutics common stock, representing 5.6% of the class.
The filing names FMR LLC as the reporting person with sole dispositive power for 3,749,048.03 shares and lists Abigail P. Johnson as having shared filing authority; signatures reference a Power of Attorney effective April 13, 2026. The exhibit list includes a 13d-1(k)(1) agreement and a referenced Exhibit 24.
Vanguard Capital Management filed a Schedule 13G disclosing beneficial ownership of 3,446,795 shares of Celldex Therapeutics Inc common stock. The filing states this equals 5.17% of the class, with sole dispositive power over 3,446,795 shares and sole voting power over 485,900 shares.
The filing attributes ownership to Vanguard Capital Management and affiliated Vanguard entities and is signed by Ashley Grim on 04/29/2026.
Celldex Therapeutics, Inc. is asking stockholders to approve several items at its virtual 2026 Annual Meeting on June 25, 2026 at 9:00 a.m. Eastern. Only holders of its 78,492,072 outstanding common shares as of April 27, 2026 may vote.
Stockholders will vote on electing nine directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, approving an amendment to the 2021 Omnibus Equity Incentive Plan that increases shares reserved for issuance by 3,400,000 to 12,900,000 and clarifies tax withholding, and an advisory say-on-pay vote for named executive officer compensation.
The proxy describes Celldex as a clinical-stage biotechnology company focused on antibody-based immunotherapies, led by barzolvolimab in multiple Phase 3 and Phase 2 programs and CDX-622 in early clinical development. It highlights a largely independent nine-member board, active committees overseeing risk, compensation and science, and policies on ethics, insider trading, stock ownership, and sustainability. Celldex ended 2025 with $519 million in cash, cash equivalents and marketable securities, which it expects to fund operations through 2027.
Celldex Therapeutics is offering 10,345,000 shares of common stock at $29.00 per share. The prospectus supplement states the public offering price of $29.00, gross proceeds of $300,005,000, and estimated net proceeds to the company of approximately $281.8 million. The underwriters have a 30-day option to purchase up to an additional 1,551,750 shares. Shares outstanding after the offering are shown as 76,894,442 (or 78,446,192 if the option is exercised), based on 66,549,442 shares outstanding as of December 31, 2025. The company intends to use proceeds to fund commercial readiness for barzolvolimab, continue clinical and preclinical development, grow its bispecific antibody platform, and for general corporate purposes.
Celldex Therapeutics entered an underwriting agreement for a public offering of 10,345,000 shares of common stock at $29.00 per share. The company expects gross proceeds of about $300 million and net proceeds of approximately $282 million, before any exercise of the underwriters’ option.
The underwriters have a 30-day option to buy up to an additional 1,551,750 shares at the same price, and the deal is expected to close on or about April 6, 2026, subject to customary conditions. Celldex plans to use the net proceeds, together with existing cash and investments, to support potential commercial launch of barzolvolimab for CSU in the United States if approved, further clinical and preclinical development of its pipeline, expansion of its bispecific antibody platform, additional pipeline programs, and general corporate purposes.
Celldex Therapeutics is offering shares of its common stock pursuant to a preliminary prospectus supplement. The supplement describes an at-the-market style shelf offering under the company’s existing registration and notes Nasdaq symbol CLDX with a last reported sale price of $31.72 per share on March 31, 2026.
The document discloses 66,549,442 shares outstanding as of December 31, 2025, outstanding options of 9,134,278 shares (weighted-average exercise price $26.49), and 2,753,587 shares reserved under equity plans. It states net tangible book value of $500.0 million or $7.51 per share as of December 31, 2025. The prospectus supplement leaves the offered share amount, offering price and estimated proceeds blank in the provided excerpt.
Celldex Therapeutics Inc ownership update: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned of Common Stock, representing 0% of the class, following an internal realignment effective January 12, 2026. The filing notes certain Vanguard subsidiaries now report separately.
Celldex Therapeutics amendment reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen beneficially owned 1,758,357 shares of common stock, representing 2.6% as of the close of business on December 31, 2025. The filing attributes shared voting and shared dispositive power of 1,758,357 shares to the reporting persons and notes Point72 entities act as investment manager and general partner. The statement clarifies these reporting persons hold no sole voting or dispositive power and provides their principal business address.